Ion World Tour 2015–Speakers
Department of Pathology, University of Cambridge, UK
Working in collaboration with the Wellcome Trust Sanger Centre and Public Health England, we have installed an Ion PGM sequencer in Makeni, Sierra Leone to provide sequence data of new ebola viral isolates.
Institute of Legal Medicine, Cologne, Germany
Peter M. Schneider is a full professor at the Institute of Legal Medicine, University of Cologne, Germany, where he is head of the Division of Forensic Molecular Genetics. He is responsible for the education of students in medicine, biology, and law, and performs routine DNA typing for criminal evidence material, identification cases, as well as relationship testing.
Queen's University Belfast, UK
Dr AJ McKnight runs the non-malignant inherited disease research labs for Queen’s University in Northern Ireland. Her primary research interest is chronic kidney disease, but she facilitates research into multiple conditions using high throughput genetics analysis approaches.
Stratified Medicine Scotland, UK
SMS-IC is a consortium of industrial partners, four medical schools and four health boards with the aim of identifying new disease-associated biomarkers to improve future clinical treatment of disease.
National Genomics Infrastructure at Science for Life Laboratory, Uppsala University, Sweden
Adam will present his experiences and data on a range of genetic study applications using the latest Ion Torrent™ technology.
National Genomics Infrastructure at Science for Life Laboratory, Uppsala University, Sweden
Inger’s team at Uppsala has been a long-standing partner for early access testing of Ion Torrent instruments and kits. The Uppsala results of transcriptome and exome studies using new Ion Torrent products will be a feature of the Ion World Tour 2015.
Sara Alvarez de Andrés
NIM Genetics, Madrid, Spain
As Medical Director for NIMGenetics, Dr Alvarez focuses on the implementation of exome sequencing in neuropediatrics. She brings a lot of experience with sequencing strategy related to different rare and inherited disorders and presents her work on whole exome sequencing for inherited disease mutation detection.
Department of Pathology and Diagnostics, University of Verona, Italy
Prof Scarpa is a founder member of the Onconetwork consortium, and was instrumental in the design and verification of the lung and colon and RNA fusion Ion AmpliSeq™ cancer panels, now CE/IVD labeled for diagnostic use. His work includes deep sequencing of solid tumour FFPE samples to investigate mutation status and correlation to clinical phenotypes, using the latest Ion Torrent technology.
BioArray, Alicante, Spain
Bioarray is a technology-based firm, specialized in genetic analysis through cutting-edge technologies in Molecular Biology, primarily DNA microarrays/CGH and NGS. Dr Alcaraz will present their work on preimplantation genetic screening using the Ion PGM™ System.
Head of Product Management, Ion Torrent™ products, Thermo Fisher Scientific
Andy oversees the development of all Ion Torrent instruments and consumables products, from the Ion PGM™, Proton™ and Chef™ Systems, to Ion AmpliSeq™ panels and the Ion PII™ chip. He will present the very latest product developments and his team will be on hand to answer your questions.
Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Portugal
Dr Costa has a wealth of experience with next generation sequencing technology for cancer mutation detection. His team have been instrumental in the early testing phases of many Ion Torrent products. He will present their recent experiences with the Ion Chef™ automated sequencing preparation and cancer gene panel workflows.
Folkhälsomyndigheten Laboratorieutveckling, Sweden
The Public Health Agency of Sweden is an expert authority that has responsibility for public health issues at a national level. The agency develops and supports activities to promote health, prevent illnesses and improve preparedness for health threats. Mattias will present his work on epidemiology studies using Ion Torrent™ sequencing.
Norwegian Forest and Landscape Institute, Norway
Using Ion Torrent sequencing to enable forestry and forestry-related environmental studies.
NOFIMA, Tromsø, Norway
NOFIMA is one of the largest institutes for applied research within the fields of fisheries, aquaculture and food research in Europe. Matthew works in the area of QTL mapping, molecular marker development and marker-assisted selection in a number of aquaculture species.
Department of Clinical Genetics, University Hospital, Copenhagen
Development of a method to detect autosomal trisomies, using semi-conductor sequencing and WISECONDOR for analysis.
We describe a leukocyte isolation method and next generation sequencing of oncogenic mutations in Circulating Tumour Cells (CTCs) isolated from blood.
We discuss adoption of cancer precision medicine into European Cancer Networks using the next generation Ion PGM™ System and the Oncomine Focus Panel (OCP) to detect actionable driver mutations in all major tumour types.
Institute of Pathology, University Hospital Basel, Switzerland
Molecular pathology laboratories are now facing a transition from classical Sanger-based sequencing to NGS. Here, we provide some examples from our experience during this phase and some possible near to come future applications.
Centrum voor Medische Genetica, Gent, Belgium
Presenting copy number analysis by shallow whole genome sequencing (CNVseq) for preimplantation genetic screening and cell free DNA analysis.
Head of the Epigenetics Lab, Research Centre for Medical Genetics, Moscow, Russia
We have analysed mutations in a wide panel of genes involved in angiomyolipoma tumorigenesis by high throughput parallel sequencing.
Head of High-throughput Sequencing Group, Laboratory of Methods of Molecular Genetics, VI Kulakov Research Center for Obstetrics, Gynecology and Perinatology, Russia
Development of an NGS technique for analysis of aneuploidies of chromosomes 18, 21 and X from cfDNA.
Research Center for Medical Genetics, Moscow, Russia
We are studying Chronic Myeloid Leukemia (CML) to identify new biomarkers for future disease monitoring and the development of new drugs.
Hôpital Archet 2, Molecular Genetics Laboratory, Nice, France
Development of future mitochondrial disease diagnostics using next generation sequencing of human mtDNA.
Laboratory of Clinical and Experimental Pathology, University of Nice Sophia Antipolis, France
Evaluation of NGS for ALK status assessment, from both tissue and liquid biospecimens in late stages non small cell lung carcinoma research.
Genetracer Biotech, Santander, Spain
GeneTracer is the only dual certification service provider in exomes and transcriptomes from Thermo Fisher Scientific in Spain, UK and Morocco. We offer a full range of genomic services to pharmaceutical companies, hospitals and research centres.
Hospital de Madrid (HM), Spain
Development and verification of predictive biomarkers for oncology. We are researching new methods that will enable personalized medicine in accordance with tumour molecular profile information.
AC-Gen Reading Life S.L., Valladolid, Spain
We present the draft genome sequences of Corynebacterium kroppenstedtii CNM633/14 and CNM632/14, multidrug-resistant and antibiotic-sensitive isolates from granulomatous mastitis samples.
Experiences with Ion PGM™ and Ion Chef™ systems with Torrent Suite™ Variant Caller and Ion Reporter™ data analysis for inherited disease research.
Nienke Van der Stoep
Clinical Genetics, Leiden University Medical Center, The Netherlands
Development and experience with custom Ion AmpliSeq™ gene panels in clinical genetics research.
Parseq Lab, St.Petersburg, Russia
We developed a tool for detection of small-size CNVs in the heterozygous state, using custom Ion AmpliSeq targeted sequencing and Ion Reporter analysis.Our algorithm could also be used for QC of samples with imbalanced amplicon content.
Laboratory for molecular biology and cytogenetics, Centre Hospitalier Lyon Sud, France
Development and evaluation of an Ion AmpliSeq™ community gene panel for the analysis of acute myelocytic leukaemia (AML).
Hospital 12 de Octubre, Madrid, Spain
Development of new molecular diagnostic and prognostic tests for different molecular alterations observed in haematological malignancies.
MD Anderson Cancer Center, Madrid, Spain
Martin De Boer
Sanquin Blood Supply Foundation, Amsterdam, The Netherlands
Ion AmpliSeq technolgoy has enabled discovery of a mutation that explains an absence of a protein (mass spec data) in a disease research project, which has remained elusive for over 10 years.
Scientific Research Institute of Physical-Chemical Medicine, Federal Medical & Biological Agency, Russia
We will present analysis of prostate cancer samples using the Ion AmpliSeq Exome Kit on the Ion Proton system. In addition, we present whole-transcriptome sequencing of tumour and normal samples using the Ion Total RNA-Seq kit on the Ion Proton system. Work is supported by the Ministry of Education and Science of the Russian Federation (grant No. 14.607.21.0068, ID RFMEFI60714X0068).
Uppsala Genome Centre, Sweden
Susana will present her experiences and data on a range of genetic study applications using the latest Ion Torrent technology.
Systems Pathology & High-Throughput Genomics Laboratory Institute of Surgical Pathology, University Hospital Zurich
Our work is aimed at systematically identifying the combinations and the chronological order of molecular alterations that accumulate during endometrial cancer progression.
Faculty of Medical Sciences, University of Groningen, The Netherlands
Presenting 16S metagenomics using the Ion PGM™ System in microbiology and outbreak management.
Sanofi R&D, Vitry, France
MicroRNAs (miRNAs) present in tissues and biofluids are emerging as sensitive and specific safety biomarkers. Macaca fascicularis (Cynomolgus monkey) is used in the pharmaceutical industry especially in drug safety evaluation. Although genome data is available for M. fascicularis, miRNAs have not been thoroughly described in this species. Talk provides insight on miRNAs in M. fascicularis.
Magna Graecia University, Catanzaro, Italy
Presenting the use of Ion AmpliSeq™ Comprehensive Cancer Panel reveling new potential targets in Colorectal Cancer.
I.R.C.C.S. Istituto Oncologico "G. Paolo II", Bari, Italy
Shareing her expience with Ion AmpliSeq™ RNA Lung Fusion Panel to select patients eligible to ALK inhibitor treatment.
Fondazione I.R.C.C.S. Istituto Nazionale Tumori, Milano, Italy
Ion semiconductor sequencing for the evaluation of IgH gene rearrangements: feasibility and applications in B-cell malignancies.
University of Brescia, Brescia, Italy
AmpliSeq™ Exome on the Ion Proton™ System: what's new with Hi-Q?
Thomas Rio Frio
Fetal aneuploidies are detected through the bioinformatic analysis of the sequencing of circulating cell-free maternal and fetal DNA present in the blood plasma using next generation sequencing. High-throughput processing of samples with high reproducibility and reduced probability of sample mixing requires a fully automatised process with complete tracking of samples and reagents from DNA extraction until the sequencing and bioinformatic analysis.
Institute Pasteur, Paris, France
Sean will be speaking about the evaluation of new technologies for microbial studies.
Premaitha Health, Manchester, UK
Detection of trisomies from cfDNA using the Ion Proton System.
For Research Use Only. Not for use in diagnostic procedures.